US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

REIN THERAPEUTICS INC

0.7838

-0.0437-5.28%

Volume:175.87K

Turnover:140.08K

Market Cap:67.05M

PE:-0.47

High:0.8350

Open:0.8200

Low:0.7800

Close:0.8275

52wk High:2.18

52wk Low:0.6940

Shares:85.54M

Float Shares:65.83M

Volume Ratio:0.38

T/O Rate:0.27%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6800

EPS(LYR):-1.9600

ROE:-96.42%

ROA:-21.02%

PB:6.57

PE(LYR):-0.40

Loading ...

Overview Company News Filings

Rein Therapeutics Inc : Maxim Group Initiates Coverage with Buy Rating; Price Target $4

THOMSON REUTERS

Rein Therapeutics expands Phase 2 RENEW trial of LTI-03 in IPF into UK

Rein Therapeutics Expands Phase 2 Renew Trial Into United Kingdom

THOMSON REUTERS

Kymera Therapeutics names Penny Carlson SVP, Development Operations

Rein Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $8 From $10

THOMSON REUTERS

Rein Therapeutics director Josef H. von Rickenbach acquires $49,525 of common shares

Rein Therapeutics announces annual shareholder meeting

BRIEF-Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering

Rein Therapeutics closes $57.5 million follow-on common stock offering

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

THOMSON REUTERS

Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Rein Therapeutics Q1 FY26 net loss widens 6.13% to $5.84 million

Rein Therapeutics CEO Brian Windsor acquires 25,000 shares for $25,000

Rein Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview

Rein Therapeutics prices 50 million-share follow-on offering at $1 per share

Rein Therapeutics Inc - Prices Public Offering of 50 Mln Shares at $1.00 per Share for $50 Mln

THOMSON REUTERS

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

BRIEF-Rein Therapeutics Provides Clinical Trial Update For Phase 2 Renew Study Of Lti-03 In Idiopathic Pulmonary Fibrosis

Rein Therapeutics enrolls 8 patients in Phase 2 IPF trial for LTI-03

Rein Therapeutics Inc Files to Offer 30 Mln Shares - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/RNTX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RNTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNTX\",,,,,undefined,":{"symbol":"RNTX","market":"US","secType":"STK","nameCN":"REIN THERAPEUTICS INC","latestPrice":0.7838,"timestamp":1789064488957,"preClose":0.8275,"halted":0,"volume":175868,"delay":0,"changeRate":-0.05280966767371596,"floatShares":65830100,"shares":85539032,"eps":-1.68,"marketStatus":"Trading","change":-0.0437,"latestTime":"09-10 14:25:55 EDT","open":0.82,"high":0.835,"low":0.78,"amount":140078.2112884,"amplitude":0.066465,"askPrice":0.7838,"askSize":26,"bidPrice":0.78,"bidSize":9446,"shortable":3,"etf":0,"ttmEps":-1.68,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789070400000},"marketStatusCode":2,"adr":0,"listingDate":1498708800000,"exchange":"NASDAQ","adjPreClose":0.8275,"preHourTrading":{"tag":"盘前","latestPrice":0.826,"preClose":0.8275,"latestTime":"09:29 EDT","volume":200,"amount":165.1,"timestamp":1789046999999,"change":-0.0015,"changeRate":-0.001813,"amplitude":0.001208},"postHourTrading":{"tag":"盘后","latestPrice":0.8287,"preClose":0.8275,"latestTime":"19:30 EDT","volume":189,"amount":156.6171,"timestamp":1788996604197,"change":0.0012,"changeRate":0.00145,"amplitude":0.00145},"volumeRatio":0.377107},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNTX\",,,,,undefined,":{"symbol":"RNTX","floatShares":65830100,"roa":"-21.02%","roe":"-96.42%","lyrEps":-1.959999,"volumeRatio":0.377107,"shares":85539032,"dividePrice":0,"high":0.835,"amplitude":0.066465,"preClose":0.8275,"low":0.78,"week52Low":0.694,"pbRate":"6.57","week52High":2.18,"institutionHeld":0,"latestPrice":0.7838,"committee":0.99451,"eps":-1.68,"divideRate":0,"volume":175868,"delay":0,"ttmEps":-1.68,"open":0.82,"prevYearClose":1.16,"prevWeekClose":0.8891,"prevMonthClose":0.7499,"prevQuarterClose":1.04,"fiveDayClose":0.7748,"twentyDayClose":0.805,"sixtyDayClose":0.9425},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RNTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"RNTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.27,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-0.1},{"market":"US","date":"2026-05-15","symbol":"RNTX","fiscalQuarterEnding":"2026/03","expectedEps":-0.49,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"pre","actualEps":-0.19},{"market":"US","date":"2026-03-26","symbol":"RNTX","fiscalQuarterEnding":"2025/12","expectedEps":-0.24,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.36},{"market":"US","date":"2025-11-14","symbol":"RNTX","fiscalQuarterEnding":"2025/09","expectedEps":-0.24,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2025-08-14","symbol":"RNTX","fiscalQuarterEnding":"2025/06","expectedEps":-0.22,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.28}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RNTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RNTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.6667,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1784606400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RNTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RNTX","date":"2026-09-09","current":-0.466667,"percent":0.20339,"low":-2.05691,"twenty":-1.496707,"median":-0.651286,"eighty":-0.520071,"high":-0.401342,"avg":-0.934307,"sd":0.503057,"marketCap":74405315},"quantilePoints":[{"date":"2025-01-17","current":-1.459659,"twenty":-1.48337,"median":-1.467068,"eighty":-1.447804,"marketCap":42681903},{"date":"2025-01-24","current":-1.630077,"twenty":-1.576729,"median":-1.478183,"eighty":-1.446322,"marketCap":47665070},{"date":"2025-01-31","current":-1.467069,"twenty":-1.741219,"median":-1.496707,"eighty":-1.462623,"marketCap":42898563},{"date":"2025-02-07","current":-1.704171,"twenty":-1.704171,"median":-1.526344,"eighty":-1.459659,"marketCap":49831664},{"date":"2025-02-14","current":-1.741218,"twenty":-1.704171,"median":-1.578211,"eighty":-1.462623,"marketCap":50914961},{"date":"2025-02-21","current":-1.98573,"twenty":-1.794566,"median":-1.630077,"eighty":-1.468551,"marketCap":58064721},{"date":"2025-02-28","current":-1.533754,"twenty":-1.79753,"median":-1.630077,"eighty":-1.47596,"marketCap":44848497},{"date":"2025-03-07","current":-1.467069,"twenty":-1.753073,"median":-1.607848,"eighty":-1.468551,"marketCap":42898563},{"date":"2025-03-14","current":-1.496707,"twenty":-1.741218,"median":-1.552277,"eighty":-1.467069,"marketCap":43765200},{"date":"2025-03-21","current":-1.430022,"twenty":-1.733809,"median":-1.518935,"eighty":-1.461141,"marketCap":41815266},{"date":"2025-03-28","current":-1.311471,"twenty":-1.704171,"median":-1.507821,"eighty":-1.431504,"marketCap":38348715},{"date":"2025-04-04","current":-1.259605,"twenty":-1.704171,"median":-1.496707,"eighty":-1.416685,"marketCap":36832099},{"date":"2025-04-11","current":-0.545587,"twenty":-1.696762,"median":-1.481888,"eighty":-1.32629,"marketCap":34308123},{"date":"2025-04-17","current":-0.577063,"twenty":-1.667124,"median":-1.474478,"eighty":-1.296652,"marketCap":36287438},{"date":"2025-04-25","current":-0.640015,"twenty":-1.630077,"median":-1.467069,"eighty":-1.259605,"marketCap":40246068},{"date":"2025-05-02","current":-0.573565,"twenty":-1.630077,"median":-1.459659,"eighty":-0.64701,"marketCap":36067514},{"date":"2025-05-09","current":-0.601544,"twenty":-1.630077,"median":-1.437431,"eighty":-0.622528,"marketCap":37826905},{"date":"2025-05-16","current":-0.825375,"twenty":-1.622667,"median":-1.430022,"eighty":-0.622528,"marketCap":51902033},{"date":"2025-05-23","current":-0.696336,"twenty":-1.607848,"median":-1.415203,"eighty":-0.629523,"marketCap":42665230},{"date":"2025-05-30","current":-0.696336,"twenty":-1.584138,"median":-1.407793,"eighty":-0.629523,"marketCap":42665230},{"date":"2025-06-06","current":-0.705061,"twenty":-1.560428,"median":-1.311471,"eighty":-0.635119,"marketCap":43199785},{"date":"2025-06-13","current":-0.712292,"twenty":-1.550055,"median":-1.296652,"eighty":-0.639316,"marketCap":43642859},{"date":"2025-06-20","current":-0.592974,"twenty":-1.539682,"median":-1.259605,"eighty":-0.638616,"marketCap":36332127},{"date":"2025-06-27","current":-0.524276,"twenty":-1.524863,"median":-1.24849,"eighty":-0.622528,"marketCap":32122917},{"date":"2025-07-03","current":-0.54597,"twenty":-1.518935,"median":-0.809312,"eighty":-0.609134,"marketCap":33452141},{"date":"2025-07-11","current":-0.535123,"twenty":-1.515971,"median":-0.771713,"eighty":-0.598047,"marketCap":32787529},{"date":"2025-07-18","current":-0.506198,"twenty":-1.508562,"median":-0.726755,"eighty":-0.578462,"marketCap":31015230},{"date":"2025-07-25","current":-0.513429,"twenty":-1.504116,"median":-0.717873,"eighty":-0.562281,"marketCap":31458305},{"date":"2025-08-01","current":-0.421229,"twenty":-1.501152,"median":-0.708677,"eighty":-0.556817,"marketCap":25809102},{"date":"2025-08-08","current":-0.417509,"twenty":-1.496707,"median":-0.703515,"eighty":-0.543648,"marketCap":25581194},{"date":"2025-08-15","current":-0.434435,"twenty":-1.490779,"median":-0.698131,"eighty":-0.532953,"marketCap":26618269},{"date":"2025-08-22","current":-0.445213,"twenty":-1.481888,"median":-0.696336,"eighty":-0.524276,"marketCap":26334772},{"date":"2025-08-29","current":-0.445213,"twenty":-1.478924,"median":-0.689114,"eighty":-0.516321,"marketCap":26334772},{"date":"2025-09-05","current":-0.537801,"twenty":-1.474478,"median":-0.673872,"eighty":-0.514875,"marketCap":31811472},{"date":"2025-09-12","current":-0.425513,"twenty":-1.472996,"median":-0.650825,"eighty":-0.513429,"marketCap":25169516},{"date":"2025-09-19","current":-0.453092,"twenty":-1.467069,"median":-0.643512,"eighty":-0.506198,"marketCap":26800874},{"date":"2025-09-26","current":-0.470822,"twenty":-1.467069,"median":-0.629523,"eighty":-0.496939,"marketCap":27849604},{"date":"2025-10-03","current":-0.457032,"twenty":-1.465587,"median":-0.622528,"eighty":-0.470507,"marketCap":27033925},{"date":"2025-10-10","current":-0.539771,"twenty":-1.459659,"median":-0.615534,"eighty":-0.469167,"marketCap":31927997},{"date":"2025-10-17","current":-0.504312,"twenty":-1.455213,"median":-0.601544,"eighty":-0.470507,"marketCap":29830538},{"date":"2025-10-24","current":-0.496432,"twenty":-1.437431,"median":-0.598047,"eighty":-0.472004,"marketCap":29364436},{"date":"2025-10-31","current":-0.61069,"twenty":-1.435949,"median":-0.596299,"eighty":-0.477169,"marketCap":36122917},{"date":"2025-11-07","current":-0.61463,"twenty":-1.430022,"median":-0.598047,"eighty":-0.479267,"marketCap":36355968},{"date":"2025-11-14","current":-0.531891,"twenty":-1.430022,"median":-0.598047,"eighty":-0.480672,"marketCap":31461895},{"date":"2025-11-21","current":-0.616035,"twenty":-1.42854,"median":-0.59455,"eighty":-0.480672,"marketCap":36275207},{"date":"2025-11-28","current":-0.700851,"twenty":-1.422612,"median":-0.598047,"eighty":-0.480672,"marketCap":41269619},{"date":"2025-12-05","current":-0.620499,"twenty":-1.415203,"median":-0.603206,"eighty":-0.482843,"marketCap":36538070},{"date":"2025-12-12","current":-0.687459,"twenty":-1.415203,"median":-0.607107,"eighty":-0.492492,"marketCap":40481028},{"date":"2025-12-19","current":-0.575859,"twenty":-1.407793,"median":-0.606928,"eighty":-0.496432,"marketCap":33909432},{"date":"2025-12-26","current":-0.589251,"twenty":-1.390011,"median":-0.606928,"eighty":-0.496432,"marketCap":34698024},{"date":"2026-01-02","current":-0.517826,"twenty":-1.341109,"median":-0.603755,"eighty":-0.496432,"marketCap":30492203},{"date":"2026-01-09","current":-0.54461,"twenty":-1.311471,"median":-0.601544,"eighty":-0.497777,"marketCap":32069386},{"date":"2026-01-16","current":-0.517826,"twenty":-1.30258,"median":-0.596299,"eighty":-0.498849,"marketCap":30492203},{"date":"2026-01-23","current":-0.598179,"twenty":-1.296652,"median":-0.593762,"eighty":-0.499215,"marketCap":35223751},{"date":"2026-01-30","current":-0.638355,"twenty":-1.293688,"median":-0.598047,"eighty":-0.499741,"marketCap":37589526},{"date":"2026-02-06","current":-0.508898,"twenty":-1.277387,"median":-0.593762,"eighty":-0.500131,"marketCap":29966475},{"date":"2026-02-13","current":-0.52229,"twenty":-1.259605,"median":-0.589251,"eighty":-0.501948,"marketCap":30755066},{"date":"2026-02-20","current":-0.49997,"twenty":-1.259605,"median":-0.58056,"eighty":-0.49997,"marketCap":29440747},{"date":"2026-02-27","current":-0.535682,"twenty":-1.255159,"median":-0.578693,"eighty":-0.50005,"marketCap":31543658},{"date":"2026-03-06","current":-0.531218,"twenty":-1.154976,"median":-0.575859,"eighty":-0.50116,"marketCap":31280794},{"date":"2026-03-13","current":-0.571395,"twenty":-0.81895,"median":-0.571395,"eighty":-0.504312,"marketCap":33646568},{"date":"2026-03-20","current":-0.580323,"twenty":-0.79198,"median":-0.575859,"eighty":-0.504312,"marketCap":34172296},{"date":"2026-03-27","current":-0.566931,"twenty":-0.783866,"median":-0.57248,"eighty":-0.504336,"marketCap":33383705},{"date":"2026-04-02","current":-0.6803,"twenty":-0.771713,"median":-0.575859,"eighty":-0.504434,"marketCap":33927228},{"date":"2026-04-10","current":-0.860214,"twenty":-0.793249,"median":-0.580323,"eighty":-0.506198,"marketCap":42899718},{"date":"2026-04-17","current":-0.955793,"twenty":-0.871458,"median":-0.580323,"eighty":-0.506198,"marketCap":47666354},{"date":"2026-04-24","current":-1.034505,"twenty":-0.955793,"median":-0.58056,"eighty":-0.506198,"marketCap":51591818},{"date":"2026-05-01","current":-0.761823,"twenty":-0.933304,"median":-0.589251,"eighty":-0.508898,"marketCap":37992888},{"date":"2026-05-08","current":-1.830837,"twenty":-0.955793,"median":-0.589251,"eighty":-0.508898,"marketCap":91305667},{"date":"2026-05-15","current":-1.768244,"twenty":-1.034505,"median":-0.593762,"eighty":-0.508898,"marketCap":88184106},{"date":"2026-05-22","current":-1.771841,"twenty":-1.259605,"median":-0.598047,"eighty":-0.508898,"marketCap":88960593},{"date":"2026-05-29","current":-2.05691,"twenty":-1.290724,"median":-0.598179,"eighty":-0.508898,"marketCap":103273325},{"date":"2026-06-05","current":-1.890133,"twenty":-1.32629,"median":-0.602094,"eighty":-0.50963,"marketCap":94899812},{"date":"2026-06-12","current":-1.715203,"twenty":-1.416685,"median":-0.60675,"eighty":-0.511716,"marketCap":86116928},{"date":"2026-06-18","current":-1.602722,"twenty":-1.430022,"median":-0.607107,"eighty":-0.512192,"marketCap":80469458},{"date":"2026-06-26","current":-1.733363,"twenty":-1.459659,"median":-0.611131,"eighty":-0.512894,"marketCap":87028710},{"date":"2026-07-02","current":-1.812304,"twenty":-1.467069,"median":-0.615082,"eighty":-0.513362,"marketCap":90992173},{"date":"2026-07-10","current":-1.848995,"twenty":-1.481888,"median":-0.616035,"eighty":-0.513362,"marketCap":92834346},{"date":"2026-07-17","current":-1.597348,"twenty":-1.504116,"median":-0.61855,"eighty":-0.513362,"marketCap":80199645},{"date":"2026-07-24","current":-1.482643,"twenty":-1.518935,"median":-0.622528,"eighty":-0.513389,"marketCap":74440529},{"date":"2026-07-31","current":-1.423159,"twenty":-1.517453,"median":-0.62645,"eighty":-0.513429,"marketCap":71453976},{"date":"2026-08-07","current":-1.343362,"twenty":-1.510044,"median":-0.629957,"eighty":-0.513969,"marketCap":67447526},{"date":"2026-08-14","current":-1.341658,"twenty":-1.504116,"median":-0.633891,"eighty":-0.51647,"marketCap":67361987},{"date":"2026-08-21","current":-1.364196,"twenty":-1.502634,"median":-0.637436,"eighty":-0.517826,"marketCap":67883775},{"date":"2026-08-28","current":-1.357083,"twenty":-1.496707,"median":-0.64701,"eighty":-0.518275,"marketCap":67529832},{"date":"2026-09-04","current":-1.462488,"twenty":-1.493894,"median":-0.650666,"eighty":-0.520071,"marketCap":72774868},{"date":"2026-09-09","current":-1.495254,"twenty":-1.496707,"median":-0.651286,"eighty":-0.520071,"marketCap":74405315}],"updateTime":1789064755476},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RNTX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2652218528","title":"Rein Therapeutics Inc : Maxim Group Initiates Coverage with Buy Rating; Price Target $4","url":"https://stock-news.laohu8.com/highlight/detail?id=2652218528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652218528?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:41","pubTimestamp":1784547719,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nFWN43M0R6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642811062","title":"Rein Therapeutics expands Phase 2 RENEW trial of LTI-03 in IPF into UK","url":"https://stock-news.laohu8.com/highlight/detail?id=2642811062","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642811062?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:02","pubTimestamp":1781179367,"startTime":"0","endTime":"0","summary":"Rein Therapeutics expanded its Phase 2 RENEW trial of LTI-03 in idiopathic pulmonary fibrosis into the U.K.No study results were presented; the update focused on trial execution and enrollment progress.The first U.K. patient was randomized; 16 patients have been enrolled across the study to date.Sites are enrolling in the U.S., Australia, and the U.K., supporting a broader international footprint for the program.Two additional countries are expected to be added in coming months, signaling continued scale-up of the Phase 2 development plan.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDLbPRBxB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","SG9999014039.USD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4139","RNTX","LU2210149790.SGD","BK4585","IE00BN0W2T93.GBP","LU2095319765.USD","IE00BN0W2W23.USD","LU0314104364.USD","BK4112","IE00B64PRP62.GBP","NDAQ","IE00BN0W2V16.EUR","LU2210150020.SGD","SG9999014013.SGD","SG9999014021.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642281684","title":"Rein Therapeutics Expands Phase 2 Renew Trial Into United Kingdom","url":"https://stock-news.laohu8.com/highlight/detail?id=2642281684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642281684?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:00","pubTimestamp":1781179201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA8QXW0G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642431386","title":"Kymera Therapeutics names Penny Carlson SVP, Development Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2642431386","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642431386?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:01","pubTimestamp":1780948885,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics appointed Penny Carlson as senior vice president, development operations to lead global clinical development operations for its oral immunology portfolio.Carlson previously served as vice president and head of global clinical development operations at Takeda, overseeing planning and execution of clinical trials.She earlier held leadership roles at Millennium Pharmaceuticals, Aileron Therapeutics, and other drugmakers.Chief Operating Officer Jeremy Chadwick will retire, remaining an adviser through year-end.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL9RPdD7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4585","IE00BGHQF748.EUR","RNTX","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014039.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00BN0W2T93.GBP","BK4139","SG9999014021.USD","BK4112","NDAQ","SG9999014005.SGD","IE00B3QW5Z07.USD","KYMR","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","SG9999014013.SGD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640958555","title":"Rein Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $8 From $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2640958555","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640958555?lang=en_us&edition=fundamental","pubTime":"2026-06-01 18:01","pubTimestamp":1780308077,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nAZN4SZUDP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639612724","title":"Rein Therapeutics director Josef H. von Rickenbach acquires $49,525 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2639612724","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639612724?lang=en_us&edition=fundamental","pubTime":"2026-05-29 08:16","pubTimestamp":1780013800,"startTime":"0","endTime":"0","summary":"Rein Therapeutics director Josef H. von Rickenbach reported open-market purchases of common stock.Total acquired: 47,060 shares at weighted average prices of $1.04 to $1.07 per share.Directly owned stake rose to 62,514 shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL96Jhxr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Rein Therapeutics director Josef H. von Rickenbach acquires $49,525 of common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639619976","title":"Rein Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2639619976","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639619976?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:45","pubTimestamp":1780001156,"startTime":"0","endTime":"0","summary":"Rein Therapeutics will hold its 2026 annual shareholder meeting virtually on July 20, 2026.Shareholders will vote on electing two Class III directors to serve until the 2029 annual meeting.A proposal seeks to raise authorized common stock to 200,000,000 shares from 100,000,000.Items also include ratifying CBIZ CPAs as auditor for the year ending Dec. 31, 2026, plus an advisory vote on executive pay.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 28, 2026, and is solely responsible for the information contained ther","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL1jzL7X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636076340","title":"BRIEF-Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2636076340","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636076340?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:02","pubTimestamp":1779109356,"startTime":"0","endTime":"0","summary":"BRIEF-Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public OfferingMay 18 (Reuters) - Rein Therapeutics Inc RNTX.O:REIN THERAPEUTICS ANNOUNCES CLOSING OF $57.5 MILLION UNDERWRITTEN","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V0SH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636738140","title":"Rein Therapeutics closes $57.5 million follow-on common stock offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2636738140","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636738140?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:03","pubTimestamp":1779105797,"startTime":"0","endTime":"0","summary":"Rein Therapeutics closed an underwritten public offering of 57,500,000 common shares at USD 1 per share, raising USD 57.5 million in gross proceeds.Deal size increased through the full exercise of the underwriters’ over-allotment option for an additional 7,500,000 shares.No warrants or other derivative securities were issued in the offering.Proceeds earmarked to fund the Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis through completion, support broader development work, working capital.Cash runway expected to extend into the first quarter of 2028 under the current operating plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief on May 18, 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL56SZLD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078277","title":"Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078277","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636078277?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:00","pubTimestamp":1779105646,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V0SH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635035352","title":"Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635035352","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635035352?lang=en_us&edition=fundamental","pubTime":"2026-05-15 22:59","pubTimestamp":1778857179,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryRein Therapeutics Inc RNTX.OQ reported a quarterly adjusted loss of 19 cents per share for the quarter ended Marc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S1OF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635632081","title":"Rein Therapeutics Q1 FY26 net loss widens 6.13% to $5.84 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635632081","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635632081?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:57","pubTimestamp":1778846259,"startTime":"0","endTime":"0","summary":"Rein Therapeutics posted a net loss of $5.84 million for three months ended March 31, 2026, widening from $5.5 million a year earlier.Operating loss narrowed to $5.23 million as total operating expenses fell to $5.23 million from $5.61 million.Other expense swung to $608,000 from other income of $108,000, driven primarily by amortization of discount on notes payable tied to promissory notes.Cash and cash equivalents totaled $4.4 million at March 31, 2026; net proceeds of about $53.1 million from a May 2026 stock offering are expected to fund operations into first quarter 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic D","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL5LVW1d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635787865","title":"Rein Therapeutics CEO Brian Windsor acquires 25,000 shares for $25,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2635787865","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635787865?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:48","pubTimestamp":1778676482,"startTime":"0","endTime":"0","summary":"Rein Therapeutics President and Chief Executive Officer Brian Windsor reported purchase of 25,000 common shares at USD 1 per share, lifting direct holdings to 27,046 shares.Windsor also reported receipt of stock options for 150,000 shares with an exercise price of USD 1.17.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL2VDvGZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Rein Therapeutics CEO Brian Windsor acquires 25,000 shares for $25,000","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634628585","title":"Rein Therapeutics Inc  expected to post a loss of 49 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634628585","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634628585?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:28","pubTimestamp":1778498888,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc  expected to post a loss of49cents a share - Earnings Preview Rein Therapeutics Inc RNTX.OQ RNTX.O is expected to  show no change in quarterly revenue when it reports  results on","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O0ZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632969333","title":"Rein Therapeutics prices 50 million-share follow-on offering at $1 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2632969333","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632969333?lang=en_us&edition=fundamental","pubTime":"2026-05-01 08:00","pubTimestamp":1777593616,"startTime":"0","endTime":"0","summary":"Rein Therapeutics priced an underwritten public offering of 50 million common shares at USD 1 per share for gross proceeds of USD 50 million.Underwriters received a 45-day option to buy up to 7.5 million additional shares to cover over-allotments.Net proceeds earmarked to fund Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis through completion.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL3tN49v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","NDAQ","SG9999014039.USD","BK4139","SG9999014021.USD","SG9999014013.SGD","LU2095319765.USD","BK4112","LU0314104364.USD","IE00B3QW5Z07.USD","RNTX","IE00BN0W2W23.USD","LU2210149790.SGD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014005.SGD","BK4588","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632336693","title":"Rein Therapeutics Inc - Prices Public Offering of 50 Mln Shares at $1.00 per Share for $50 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2632336693","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632336693?lang=en_us&edition=fundamental","pubTime":"2026-05-01 08:00","pubTimestamp":1777593600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nTUA6GY14C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632934256","title":"Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2632934256","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632934256?lang=en_us&edition=fundamental","pubTime":"2026-05-01 08:00","pubTimestamp":1777593600,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, April  30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. (\"Rein\" or the \"Company\") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/01/3285633/28652/en/Rein-Therapeutics-Announces-Pricing-of-50-Million-Underwritten-Public-Offering-of-Common-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","RNTX","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631191245","title":"BRIEF-Rein Therapeutics Provides Clinical Trial Update For Phase 2 Renew Study Of Lti-03 In Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2631191245","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631191245?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:18","pubTimestamp":1777465113,"startTime":"0","endTime":"0","summary":"BRIEF-Rein Therapeutics Provides Clinical Trial Update For Phase 2 Renew Study Of Lti-03 In Idiopathic Pulmonary FibrosisApril 29 (Reuters) - Rein Therapeutics Inc RNTX.O:REIN THERAPEUTICS PROVIDES CL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nFWN41C0U4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631551623","title":"Rein Therapeutics enrolls 8 patients in Phase 2 IPF trial for LTI-03","url":"https://stock-news.laohu8.com/highlight/detail?id=2631551623","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631551623?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:03","pubTimestamp":1777464211,"startTime":"0","endTime":"0","summary":"Rein Therapeutics reported accelerated enrollment in Phase 2 RENEW study of LTI-03 for idiopathic pulmonary fibrosis.Study enrolled 8 patients to date, with 2 more expected this week.Enrollment started in March 2026, with additional patients being added on a regular basis.Trial sites are active in United States, Australia, Poland, with United Kingdom and Germany expected to open soon.No clinical results have been presented yet, with update focused on enrollment progress and site expansion.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL5V4WTb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BK4585","NDAQ","IE00BN0W2T93.GBP","BK4588","SG9999014039.USD","IE00B64PRP62.GBP","RNTX","LU2210149790.SGD","BK4112","SG9999014013.SGD","LU0314104364.USD","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","LU2095319765.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631791531","title":"Rein Therapeutics Inc Files to Offer 30 Mln Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2631791531","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631791531?lang=en_us&edition=fundamental","pubTime":"2026-04-29 05:31","pubTimestamp":1777411910,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B0RQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":42,"code":"91000000","status":"200"}]}}